IHS Chemical Week

EnviroTech :: Regulatory

FDA Criticized for Negligence in Baxter Heparin Case

4:25 PM MST | March 3, 2008 | Deepti Ramesh

The U.S. FDA has been heavily criticized by Congress for not inspecting a plant in China that manufactures the active pharmaceutical ingredient (API) for heparin, a blood-thinning drug made by Baxter International (Deerfield, IL). Heparin has caused four deaths and had other harmful effects on a growing number of patients in the U.S. FDA confused the identity of the company that operates the Chinese API plant with that of another company with a similar name, when the API manufacturer applied for approval of its facility, reports say. The other company had been...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa